Proteomic Adaptation of <i>Streptococcus pneumoniae</i> to the Human Antimicrobial Peptide LL-37.
Mücke. Pierre-Alexander PA; Maaß. Sandra S; Kohler. Thomas P TP; Hammerschmidt. Sven S; Becher. Dörte D
Key Findings
- Physiological levels of LL‑37 cause widespread changes in the pneumococcal proteome.
- The bacteria employ known resistance tactics such as repulsion, export, and degradation of LL‑37.
- A previously unlinked protein, the teichoic acid flippase TacF, appears to contribute to antimicrobial peptide resistance.
Practical Outcomes
- For biohackers, this means that simply boosting LL‑37 levels is unlikely to stop pneumococcal infections because the bacteria can adapt. The new resistance proteins identified could become future drug targets, but there are no immediate changes to dosing or protocols based on this work.
Summary
The study looked at how the pneumonia‑causing bacteria Streptococcus pneumoniae changes its protein makeup when exposed to the human immune peptide LL‑37. It found that the bugs use known tricks to dodge the peptide and also uncovered a few new proteins that might help them survive.
Abstract
Secreted antimicrobial peptides (AMPs) are an important part of the human innate immune system and prevent local and systemic infections by inhibiting bacterial growth in a concentration-dependent manner. In the respiratory tract, the cationic peptide LL-37 is one of the most abundant AMPs and capable of building pore complexes in usually negatively charged bacterial membranes, leading to the destruction of bacteria. However, the adaptation mechanisms of several pathogens to LL-37 are already described and are known to weaken the antimicrobial effect of the AMP, for instance, by repulsion, export or degradation of the peptide. This study examines proteome-wide changes in <i>Streptococcus pneumoniae</i> D39, the leading cause of bacterial pneumonia, in response to physiological concentrations of LL-37 by high-resolution mass spectrometry. Our data indicate that pneumococci may use some of the known adaptation mechanisms to reduce the effect of LL-37 on their physiology, too. Additionally, several proteins seem to be involved in resistance to AMPs which have not been related to this process before, such as the teichoic acid flippase TacF (SPD_1128). Understanding colonization- and infection-relevant adaptations of the pneumococcus to AMPs, especially LL-37, could finally uncover new drug targets to weaken the burden of this widespread pathogen.
Study Information
pubmed
2020
2020-03-14T00:00:00.000Z
10.3390/microorganisms8030413
15
57